Financial
information
Hofseth BioCare aim to serve the financial market with precise and relevant information about the company to ensure that the share price reflects the underlying values and future prospects. In this section you will find the latest news, presentations, reports and other useful information.
Stock Exchange Notices
- 2019-05-28: Hofseth Biocare ASA: Disclosure of large shareholdings in Hofseth BioCare ASA
- 2019-05-10: Hofseth Biocare ASA: First Quarter 2019 Financial Report
- 2019-04-26: Hofseth Biocare ASA: Completed Annual General Meeting
- 2019-04-24: Hofseth Biocare ASA: PROXIES TO VOTE FOR 62.43 % OF THE SHARES AT AGM
- 2019-04-05: Hofseth BioCare ASA: Call for Annual General Meeting
- 2019-04-03: Hofseth Biocare ASA: HUMAN AND PET NUTRITION CONTRACTS UPDATE
- 2019-03-15: Hofseth Biocare ASA: HBC Annual Report 2018
- 2019-03-08: Hofseth Biocare ASA: NEW 128-DAY STUDY ON COLLAGO® SHOW INCREASED ENERGY AND ANTI-INFLAMMATORY EFFECTS
- 2019-02-08: Hofseth Biocare ASA: HBC Fourth Quarter 2018 Financial Report
- 2019-01-24: Hofseth Biocare ASA: CORRECTION: MANDATORY NOTIFICATION OF TRADE, PRIMARY INSIDER IN HOFSETH BIOCARE ASA
Archive
- Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE, PRIMARY INSIDER IN HOFSETH BIOCARE ASA
- Hofseth BioCare ASA: NEW STUDY SHOWS CALGO® IS SUPERIOR TO TRADITIONAL CALCIUM SOURCES ON OSTEOBLAST AND CALCIUM DEPOSITION
- Hofseth Biocare ASA: HBC Third Quarter 2018 Financial Report
- Hofseth Biocare ASA: REGISTRATION OF SHARE CAPITAL INCREASE
- Hofseth Biocare ASA: Result of the subsequent offering
- Hofseth Biocare ASA: LAST DAY OF SUBSCRIPTION PERIOD
- Hofseth Biocare ASA: New study and US provisional patent filed on regulation of oxidative protective genes in human cells with ProGo for treatment of IBD, such as ulcerative colitis and Crohn's
- Hofseth Biocare ASA: HBC Second Quarter 2018 Financial Report
- Hofseth Biocare ASA: PUBLICATION OF PROSPECTUS - FURTHER INFORMATION ABOUT THE SUBSEQUENT OFFERING
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
- Hofseth Biocare ASA: Completed Extraordinary General meeting and approved private placement and repair issue
- Hofseth Biocare ASA: Notice of Extraordinary General Meeting
- Hofseth Biocare ASA: CORRECTION: PRIVATE PLACEMENT COMPLETED - MANDATORY NOTIFICATION OF TRADE, DISCLOSURE OF LARGE SHAREHOLDINGS
- Hofseth Biocare ASA: PRIVATE PLACEMENT COMPLETED - MANDATORY NOTIFICATION OF TRADE, DISCLOSURE OF LARGE SHAREHOLDINGS
- Hofseth Biocare ASA: Key information relating to the repair issue
- Hofseth Biocare ASA: HBC launches private placement from NOK 120 to 140 million, consolidates its factories, improves the production process and reduces its production costs
- Hofseth Biocare ASA: HBC First Quarter 2018 Financial Report
- Hofseth Biocare ASA: Disclosure of large shareholdings in Hofseth BioCare ASA
- Hofseth Biocare ASA : Completed Annual General Meeting in HBC
- Hofseth Biocare ASA: PROXIES TO VOTE FOR 40.69 % OF THE SHARES AT AGM - DISCLOSURE OF LARGE SHAREHOLDING
- Hofseth Biocare ASA: Call for Annual General Meeting
- Hofseth Biocare ASA: HBC Annual Report 2017
- Hofseth BioCare ASA: HBC Fourth Quarter 2017 Financial Report
- Hofseth Biocare ASA: Financial update
- Hofseth Biocare ASA: HBC Third Quarter 2017 Financial Report
- Hofseth Biocare ASA: HBC enters into a new NOK 35m financing agreement
- Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE, PRIMARY INSIDER IN HOFSETH BIOCARE ASA
- Hofseth Biocare ASA: Financial Update
- Hofseth Biocare ASA: CHANGES IN BOARD OF DIRECTORS - OLA HOLEN TO FUNCTION AS NEW INTERIM CHAIRMAN
- Hofseth Biocare ASA: Mandatory notification of trade, primary insider in HBC
- Hofseth Biocare ASA: HBC Second Quarter 2017 Financial report
- Hofseth Biocare ASA: Roger Hofseth new CEO in HBC
- Hofseth Biocare ASA : Completed annual general meeting
- Hofseth Biocare ASA: First Quarter 2017 Financial Report
- Hofseth Biocare ASA: Call for Annual General Meeting
- Hofseth Biocare ASA: HBC Annual Report 2016 approved and completes sale and long-term leaseback contracts
- Hofseth Biocare ASA: Completes Extraordinary General Meeting in HBC
- Hofseth Biocare ASA: PROXIES TO VOTE FOR 20.06 % OF THE SHARES AT EGM - DISCLOSURE OF LARGE SHAREHOLDING
- Hofseth Biocare ASA: Disclosure of large shareholdings in Hofseth BioCare ASA
- Hofseth Biocare ASA: ENTERS INTO AGREEMENT FOR SALE AND LONG TERM LEASE CONTRACTS OF PROPERTIES - CALL FOR GENERAL MEETING
- Hofseth Biocare ASA: Fourth Quarter 2016 Financial Report
- Hofseth Biocare ASA: SHARE PURCHASE
- Hofseth Biocare ASA :Mandatory notification of trade, primary insider in HBC
- Hofseth Biocare ASA: Mandatory notification of trade, primary insider in HBC
- Hofseth Biocare ASA: HBC receive additional food safety certification and several grants on OmeGo and ProGo patents in target markets
- Hofseth Biocare ASA: Third Quarter 2016 Financial Report
- Hofseth Biocare ASA: Hofseth BioCare inngår avtale med Morene Produkter om distribusjon av Brilliant Lakseolje
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
- Hofseth Biocare ASA: Final result of the Subsequent Offering
- Hofseth Biocare ASA: End of subscription period in the Subsequent Offering and last day of trading in subscription rights
- Hofseth Biocare ASA: Expiry of subscription period and last day of trading in subscription rights 17 October 2016
- Hofseth BioCare ASA: Grant of Patent in the European Union
- Hofseth Biocare ASA: Start of subscription period in the Subsequent Offering
- Hofseth Biocare ASA: Prospectus
- Hofseth Biocare ASA: Correction of minutes from Extraordinary General Meeting held 20 September 2016
- Hofseth Biocare ASA: New Share Capital registered
- Hofseth Biocare ASA: Disclosure of large shareholdings and subscription of primary insiders
- Hofseth Biocare ASA: Completes extraordinary general meeting and approves private placements of NOK 165m
- Hofseth Biocare ASA: Proxy Rights at Extraordinary General Meeting
- Hofseth Biocare ASA: Key Information regarding the subsequent offering in Hofseth BioCare ASA
- Hofseth BioCare ASA: Notice of Extraordinary General Meeting
- Hofseth BioCare ASA: Second Quarter 2016 Financial Report
- Hofseth BioCare ASA: Equity issue of minimum NOK 165m as part of recapitalization plan under ongoing turnaround project - Alliance Seafoods becomes a key shareholder
- Hofseth BioCare ASA: Key OmeGo(TM) patent notice of allowance in the US and new study on ProGo(TM)
- Hofseth Biocare ASA: Completed annual general meeting - cancellation of subsequent offering
- Hofseth Biocare ASA: Proxy Rights at Annual General Meeting
- Hofseth Biocare ASA: CORRECTION: Key information in relation to the repair issue to be carried out by Hofseth BioCare ASA
- Hofseth Biocare ASA: First Quarter 2016 Financial Report
- Hofseth Biocare ASA: Norwegian salmon protein wins international health award
- Hofseth Biocare ASA: CORRECTION: Key information in relation to the repair issue to be carried out by Hofseth BioCare ASA
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
- Hofseth Biocare ASA: Key information in relation to the repair issue to be carried out by Hofseth BioCare ASA
Why Hofseth BioCare?
- New advanced proprietary process technology
- Producing premium products
- Attractive market proposition
- State of the art production facilities
- Attractive partner model for further growth
- Upside potential within pharma segments
- Management with highly relevant experience
